U.S. Inflammatory Bowel Disease Treatment Market Size & Outlook

The inflammatory bowel disease treatment market in the United States is expected to reach a projected revenue of US$ 14,078.1 million by 2030. A compound annual growth rate of 3% is expected of the United States inflammatory bowel disease treatment market from 2024 to 2030.

Revenue, 2023 (US$M)
$11,411.1
Forecast, 2030 (US$M)
$14,078.1
CAGR, 2024 - 2030
3%
Report Coverage
U.S.

U.S. inflammatory bowel disease treatment market, 2018-2030 (US$M)

U.S.

Related Markets

U.S. inflammatory bowel disease treatment market highlights

  • The U.S. inflammatory bowel disease treatment market generated a revenue of USD 11,411.1 million in 2023 and is expected to reach USD 14,078.1 million by 2030.
  • The U.S. market is expected to grow at a CAGR of 3% from 2024 to 2030.
  • In terms of segment, crohn's disease was the largest revenue generating type in 2023.
  • Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.


Inflammatory bowel disease treatment market data book summary

Market revenue in 2023USD 11,411.1 million
Market revenue in 2030USD 14,078.1 million
Growth rate3% (CAGR from 2023 to 2030)
Largest segmentCrohn's disease
Fastest growing segmentUlcerative Colitis
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCrohn's Disease, Ulcerative Colitis
Key market players worldwideAbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare


Other key industry trends

  • In terms of revenue, U.S. accounted for 55.0% of the global inflammatory bowel disease treatment market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
  • Canada is the fastest growing regional market in North America and is projected to reach USD 855.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Inflammatory Bowel Disease Treatment Market Scope

Inflammatory bowel disease treatment market segmentation & scope
Crohn's Disease
Ulcerative Colitis
Aminosalicylates
Corticosteroids
TNF Inhibitors
IL Inhibitors
Anti-integrin
JAK Inhibitors
Other Drug Class
Oral
Injectable
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Inflammatory Bowel Disease Treatment Market Companies

Name Profile # Employees HQ Website

U.S. inflammatory bowel disease treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.


Crohn's disease was the largest segment with a revenue share of 62.28% in 2023. Horizon Databook has segmented the U.S. inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.


The U.S. IBD market is observing a major shift in dynamics, wherein doctors are increasingly preferring the usage of newly launched products by companies such as AbbVie and Bristol Myers Squibb over other conventional therapies.

The prescription patterns is witnessing a considerable shift with the entry of Skyrizi (in June 2022) and Zeposia (in May 2022). U.S.-based companies, such as Prometheus Biosciences and Pfizer, are providing positive Phase II stage clinical trial results for their products PRA023 (results announced in December 2022) and RVT3101 (result announced in January 2023), respectively.

The growing competition between the two companies is anticipated to provide better treatment options to patients in the upcoming years and boost =IBD market growth. Initiatives undertaken by various organizations to address the challenges in IBD research are expected to boost market growth over the forecast period.

Reasons to subscribe to U.S. inflammatory bowel disease treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of U.S. inflammatory bowel disease treatment market databook

  • Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the U.S. inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

U.S. inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)

U.S. Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)

U.S. inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more